# Rediscovering Diazaborines: Synthesis and Bioactivity Profiling of Boron-Containing FabI Inhibitors against Gram-Negative Bacteria

## TL;DR

This study explores diazaborine compounds as potential antibiotics against drug-resistant Gram-negative bacteria, showing promising activity and synergy with existing drugs.

## Contribution

The study introduces diazaborines as novel FabI inhibitors with optimized structure and demonstrates their efficacy and synergy against Gram-negative pathogens.

## Key findings

- Diazaborine scaffold 11 showed MIC of 6.25 μM against E. coli with low cytotoxicity and high plasma stability.
- Compound 11 synergized with colistin (FICI 0.25) and rescued Galleria mellonella larvae from E. coli infection.
- Structure–activity relationships were established, linking FabI inhibition to antimicrobial activity.

## Abstract

In this study, we investigated the potential of diazaborine
compounds
for antibacterial drug development. Most promising diazaborines demonstrated
activity against several Gram-negative pathogens including Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, and Salmonella enterica ser. Typhimurium. For a subset
of diazaborines, we showed inhibitory activity against isolated FabI
(enoyl-acyl carrier protein reductase) enzyme aligning with antimicrobial
activity, suggesting a mechanism of action via the FabI enzyme and
providing early information on structure–activity relationships.
Optimized diazaborine scaffold 11 features an amino group
in a meta-relative position to the sulfonamide group and exhibited
the most favorable bioactivity profile, showing MIC of 6.25 μM
against E. coli, low cytotoxicity,
and high stability in human plasma. Furthermore, diazaborine 11 had synergistic effect with colistin (FICI 0.25) and preliminary
data show that it may rescue Galleria mellonella larvae from lethal E. coli infection
at the therapeutic dose of 1.13 and 2.81 mg/kg, demonstrating efficacy
similar to ciprofloxacin.